EUVIMEDOdkrijte EUVIMED
Open access · CC BY-NC 4.0

Vulvar cancer incidence and net survival in Sweden 1960 to 2019: A population‐based national study

Louise Moberg iD, Avalon Sundqvist iD, Erik Holmberg iD, Paul W Dickman iD, Christer Borgfeldt iD

Acta Obstetricia et Gynecologica Scandinavica · 2024

DOI: 10.1111/aogs.14747 ↗

At a glance

Journal article in Acta Obstetricia et Gynecologica Scandinavica, 2024. Written by Louise Moberg and 4 co-authors. Institution: Department of Obstetrics and Gynecology, Skåne University Hospital Lund, Lund University, Lund, Sweden. Major MEDLINE topics: Vulvar Neoplasms, Melanoma, Carcinoma, Squamous Cell, Skin Neoplasms. Cited 11 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC 4.0).

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Introduction

Vulvar cancer is a rare gynecological cancer affecting mostly older women. The aim of this population‐based study was to investigate the incidence and net survival of vulvar cancer in Swedish women from 1960 to 2019. Material and methods Data were retrieved from the mandatory Swedish Cancer Registry consisting of all women diagnosed with vulvar cancer between 1960 and 2019. Only women with a morphologically verified diagnosis of vulvar cancer were included. The individuals were then further matched with the Swedish Death Registry up until May 31, 2020.

Results

In total, 8499 women were included with the following morphologies: squamous cell carcinoma 7250 (85.8%), malignant melanoma 539 (6.4%), adenocarcinoma 401 (4.8%) and other: 259 (3.1%). More than 50% of vulvar cancer cases occurred in women aged between 65 and 84 years of age. The 5‐year age‐standardized net survival increased from 53.0% (95% confidence interval [CI] 48.9–57.5) in 1960 to 72.1% (95% CI 68.8–75.5) in 2019. The proportion of adenocarcinoma among all cases increased from 2.0% to 8.7% between the 1960s and 2010s and an increase in age‐standardized 5‐year net survival was found for adenocarcinoma.

Conclusions

The age‐standardized incidence of vulvar cancer cases in Sweden was stable between 1960 and 2019. During the study period, an increase in adenocarcinoma and a decrease in malignant melanoma cases was found. Five‐year net survival increased by 20 percent units during the study period. For squamous cell carcinoma, an increased age‐specific 5‐year net survival was observed for all age groups, apart for women aged ≥85.

Subjects

MeSH terms (MEDLINE)

Vulvar NeoplasmsMelanomaCarcinoma, Squamous CellSkin NeoplasmsAdenocarcinomaHumansFemaleAgedAged, 80 and overIncidenceSweden

Author keywords

epidemiologyincidenceregistrysurvivalvulvar neoplasms

Authors and institutions

  • Department of Obstetrics and Gynecology, Skåne University Hospital Lund, Lund University, Lund, Sweden.
  • Department of Oncology, University of Gothenburg Institute of Clinical Sciences, Gothenburg, Sweden.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.

ORCID profiles: Louise Moberg, Avalon Sundqvist, Erik Holmberg, Paul W Dickman, Christer Borgfeldt

Cite

APA

Moberg, L., Sundqvist, A., Holmberg, E., Dickman, P. W., & Borgfeldt, C. (2024). Vulvar cancer incidence and net survival in Sweden 1960 to 2019: A population‐based national study. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.14747

Vancouver

Moberg L, Sundqvist A, Holmberg E, Dickman PW, Borgfeldt C. Vulvar cancer incidence and net survival in Sweden 1960 to 2019: A population‐based national study. Acta Obstetricia et Gynecologica Scandinavica. 2024. doi:10.1111/aogs.14747

BibTeX
@article{Moberg2024,
  author = {Moberg, Louise and Sundqvist, Avalon and Holmberg, Erik and Dickman, Paul W and Borgfeldt, Christer},
  title = {Vulvar cancer incidence and net survival in Sweden 1960 to 2019: A population‐based national study},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2024},
  doi = {10.1111/aogs.14747}
}
Start for free →